Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule ...

Acerand Therapeutics Initiates First-in-Human Phase I Clinical Trial of ACE-232, a Novel CYP11A1 Inhibitor for Advanced Prostate Cancer Acerand Therapeutics, a clinical-stage biotech company ...

a novel oral inhibitor of CYP11A1. The trial is being conducted in patients with metastatic castration-resistant prostate cancer (mCRPC).

ACE-232 is a potent CYP11A1 inhibitor showing efficacy in preclinical models resistant to current mCRPC therapies. The phase 1 trial will enroll 67 patients to evaluate safety, tolerability, and ...